How long does it take to translate research findings into routine healthcare practice?—the case of biological drugs for rheumatoid arthritis in Brazil

Abstract

Background The literature reports long time lags between the several processes involved in the translation of drug research and development into clinical application. To expedite these processes, translational research has emerged as a process that can be applied to reduce the lag between scientific discoveries and their practical application. Thus, the objective of this study was to estimate the time lag in translational research of biological drugs for the treatment of rheumatoid arthritis included in the Brazilian Unified Health System [ Sistema Único de Saúde (SUS)]. Methods A descriptive retrospective study was conducted based on secondary data loaded by SUS users in public sources and systems to estimate the time lag between the publication of phase I clinical trial results to drug use in clinical settings. The dates of translational research activities were identified from markers and steps. Structured searches were conducted in the literature and reports from the National Commission for the Incorporation of Technologies in the SUS (Conitec) as well as from health authorities, and analyzed. Results Between 2012 and 2019, SUS included five biological agents for the treatment of rheumatoid arthritis. The mean time lag from clinical development to use of these agents was 11.13 years (range, 8.57 to 12.90 years). The mean time lag for the stages of translational research were 5.30 (T1—basic research to clinical research), 5.08 (T2—clinical research to research synthesis), and 0.75 (T3—research synthesis to evidence-based practice) years. A shorter time lag was observed in the Brazilian case when it was possible to compare with other studies. Conclusions The estimated time lag of biological drugs used in the treatment of rheumatoid arthritis was determined based on the translational research steps model adapted to the Brazilian context. Brazil has instituted legal frameworks that set deadlines for sanitary registration, health technology assessment (HTA), and the availability of drugs in the SUS, thus, allowing for a reduced stage T2 time lag. Nevertheless, improvements are still required in stages T1 and T2, especially in publishing the results of clinical trials.

An AI Approach to Identifying Novel Therapeutics for Rheumatoid Arthritis

“…Despite the advancements and enhanced knowledge gained from innovative research, the translation of these into therapeutic benefits has not been fully realised. A study in Brazil found the average time lag from the clinical development to the application of biological drugs was 11.3 years [48]. Upadacitinib is the most recent treatment approved for RA with clinical trials to determine safety and efficacy in 2015 and approved for use in the UK in April 2021 [49].…”

Elevated serum IL-6 levels predict treatment interruption in patients with moderate to severe psoriasis: a 6-year real-world cohort study

“… 15 The Brazilian Unified Health System (SUS) is responsible for the provision of healthcare and pharmaceutical assistance to over 200 million people. 16 Therefore, the Brazilian SUS constitutes a privileged scenario for pharmacovigilance. 17 The national protocol regarding the sequence of medications used in psoriasis is not different from most international recommendations.…”

Implementation of health technologies in Brazil: analysis of federal guidelines for the public health system

“…The process of inclusion, alteration, and exclusion of health technologies, focused mainly on hard technologies such as medicines, procedures, and medical materials, adopts well-defined criteria and an organized flow to analyze internal and external demands on the SUS 9 , linked to a transparent administrative process with well-defined deadlines, consolidated from 2011 9,11 . In contrast to a welldefined evaluation stage 9 that includes significant investments in innovative technologies 12 , implementing incorporated technologies, that is, their effective use in clinical practice, is still a challenge in Brazil 13,14 . Although the PNGTS publication and Law No.…”